Systemic Therapy for Bladder Cancer Finally Comes into a New Age

References

• Siegel RL , MillerKD, JemalA. Cancer statistics, 2015. CA Cancer J. Clin.65(1), 5–29 (2015).
   PubMed Web of Science ®Google Scholar
• Ploussard G , DaneshmandS, EfstathiouJAet al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur. Urol.66(1), 120–137 (2014).
   PubMed Web of Science ®Google Scholar
• Stein JP , LieskovskyG, CoteRet al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Gakis G , EfstathiouJ, LernerSPet al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur. Urol.63(1), 45–57 (2013).
   PubMed Web of Science ®Google Scholar
• Chen RC , ShipleyWU, EfstathiouJA, ZietmanAL. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J. Natl Comp. Canc. Netw.11(8), 952–960 (2013).
   PubMed Web of Science ®Google Scholar
• Grossman HB , NataleRB, TangenCMet al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349(9), 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Coppin C , GospodarowiczMK, JamesKet al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.14(11), 2901–2907 (1996).
   PubMed Web of Science ®Google Scholar
• Clark PE , SpiessPJ, AgarwalNet al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. 1.2016 (2016). www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
   Google Scholar
• Witjes J , ComperatE, CowanNet al. EAU guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology. (2015). https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.
   Google Scholar
• Burger M , MuldersP, WitjesW. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur. Urol.61(5), 1070–1071 (2012).
   PubMed Web of Science ®Google Scholar
• Zaid HB , PatelSG, StimsonCet al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology83(1), 75–80 (2014).
   PubMed Web of Science ®Google Scholar
• Cowan NG , ChenY, DownsTet al. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv. Urol.2014 (2014).
   PubMedGoogle Scholar
• Knollman H , GodwinJL, JainR, WongYN, PlimackER, GeynismanDM. Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther. Adv. Urol.7(6), 312–330 (2015).
   PubMedGoogle Scholar
• Reardon ZD , PatelSG, ZaidHBet al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur. Urol.67(1), 165–170 (2015).
   PubMed Web of Science ®Google Scholar
• International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group , GriffithsG, HallR, SylvesterR, RaghavanD, ParmarMK. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol.29(16), 2171–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet354(9178), 533–540 (1999).
   Google Scholar
• Citron ML , BerryDA, CirrincioneCet al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol.21(8), 1431–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Sternberg C , De MulderP, SchornagelJet al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J. Clin. Oncol.19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• Sternberg C , De MulderP, SchornagelJet al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer42(1), 50–54 (2006).
   PubMed Web of Science ®Google Scholar
• Plimack ER , Hoffman-CensitsJH, ViterboRet al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter Phase II study with molecular correlates of response and toxicity. J. Clin. Oncol.32(18), 1895–1901 (2014).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , JacobusS, BellmuntJet al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J. Clin. Oncol.32(18), 1889–1894 (2014).
   PubMed Web of Science ®Google Scholar
• Von Der Maase H , SengelovL, RobertsJTet al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Galsky MD , PalSK, ChowdhurySet al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer121(15), 2586–2593 (2015).
   PubMed Web of Science ®Google Scholar
• Zargar H , EspirituPN, FaireyASet al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol.67(2), 241–249 (2015).
   PubMed Web of Science ®Google Scholar
• Apolo AB , KimJW, BochnerBHet al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol. Oncol.32(5), 637–644 (2014).
   PubMed Web of Science ®Google Scholar
• Plimack ER , DunbrackRL, BrennanTAet al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol.68(6), 959–967 (2015).
   PubMed Web of Science ®Google Scholar
• Van Allen EM , MouwKW, KimPet al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov.4(10), 1140–1153 (2014).
   PubMed Web of Science ®Google Scholar
• Stein JP , LieskovskyG, CoteRet al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Donat SM , ShabsighA, SavageCet al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol.55(1), 177–185 (2009).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , SolsonaE, EstebanEet al. Randomized Phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 4–8 June 2010.
   Google Scholar
• Sternberg CN , SkonecznaI, KerstJMet al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised Phase 3 trial. Lancet Oncol.16(1), 76–86 (2015).
   PubMed Web of Science ®Google Scholar
• Cognetti F , RuggeriE, FeliciAet al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized Phase III trial. Ann. Oncol.23(3), 695–700 (2011).
   PubMed Web of Science ®Google Scholar
• Leow JJ , Martin-DoyleW, RajagopalPSet al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol.66(1), 42–54 (2014).
   PubMed Web of Science ®Google Scholar
• Galsky MD , StenslandKD, MoshierEet al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J. Clin. Oncol. doi: 10.1200/JCO.2015.64.1076 (2016) ( Epub ahead of print).
   Google Scholar
• Guibert N , DelaunayM, MazièresJ. Targeting the immune system to treat lung cancer: rationale and clinical experience. Ther. Adv. Respir. Dis.9(3), 105–120 (2015).
   PubMed Web of Science ®Google Scholar
• Carthon BC , WolchokJD, YuanJet al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res.16(10), 2861–2871 (2010).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02662309. https://clinicaltrials.gov/ct2/show/NCT02662309.
   Google Scholar
• Clinical Trials Database: NCT02451423. https://clinicaltrials.gov/ct2/show/NCT02451423.
   Google Scholar
• Clinical Trials Database: NCT02365766. https://clinicaltrials.gov/ct2/show/NCT02365766.
   Google Scholar
• Clinical Trials Database: NCT02690558. https://clinicaltrials.gov/ct2/show/NCT02690558.
   Google Scholar
• Macfarlane AWT , JillabM, PlimackERet al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol. Res.2(4), 320–331 (2014).
   PubMed Web of Science ®Google Scholar
• Eggermont AMM , Chiarion-SileniV, GrobJ-Jet al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, Phase 3 trial. Lancet Oncol.16(5), 522–530 (2015).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02450331. https://clinicaltrials.gov/ct2/show/NCT02450331.
   Google Scholar
• Clinical Trials Database: NCT02632409. https://clinicaltrials.gov/ct2/show/NCT02632409.
   Google Scholar
• Petrylak DP , PowlesT, BellmuntJet al. A Phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 29 May–2 June 2015.
   Google Scholar
• Plimack ER , BellmuntJ, GuptaSet al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J. Clin. Oncol. (Meeting Abstracts)33(15 Suppl.), 4502 (2015).
   Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ, PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase 2 trial. Lancet387(10031), 1909–1920 (2016).
   PubMed Web of Science ®Google Scholar
• Weber JS , KählerKC, HauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol.30(21), 2691–2697 (2012).
   PubMed Web of Science ®Google Scholar
• Yagoda A , WatsonRC, Gonzalez-VitaleJC, GrabstaldH, WhitmoreW. Cis-dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat. Rep.60(7), 917–923 (1976).
   PubMedGoogle Scholar
• Galsky MD , HahnNM, RosenbergJet al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol.12(3), 211–214 (2011).
   PubMed Web of Science ®Google Scholar
• Pal SK , MilowskyMI, PlimackER. Optimizing systemic therapy for bladder cancer. J. Natl Comp. Canc. Netw.11(7), 793–804 (2013).
   PubMed Web of Science ®Google Scholar
• Von Der Maase H , HansenS, RobertsJet al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• Bamias A , DafniU, KaradimouAet al. Prospective, open-label, randomized, Phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann. Oncol.24(4), 1011–1017 (2013).
   PubMed Web of Science ®Google Scholar
• Linardou H , AravantinosG, EfstathiouEet al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology64(3), 479–484 (2004).
   PubMed Web of Science ®Google Scholar
• De Santis M , BellmuntJ, MeadGet al. Randomized Phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol.JCO.3571(2011), 2037 (2011).
   Google Scholar
• Stadler WM , KuzelT, RothB, RaghavanD, DorrFA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol.15(11), 3394–3398 (1997).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , ThéodoreC, DemkovTet al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
   PubMed Web of Science ®Google Scholar
• Lorusso V , PolleraC, AntimiMet al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur. J. Cancer34(8), 1208–1212 (1998).
   PubMed Web of Science ®Google Scholar
• Mccaffrey JA , HiltonS, MazumdarMet al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol.15(5), 1853–1857 (1997).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ , BroomeCM, HussainM, GutheilJC, MarkowitzAB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol.20(4), 937–940 (2002).
   PubMed Web of Science ®Google Scholar
• Ko Y-J , CanilCM, MukherjeeSDet al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, Phase 2 study. Lancet Oncol.14(8), 769–776 (2013).
   PubMed Web of Science ®Google Scholar
• Lee J-L , AhnJ-H, ParkSHet al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest. New Drugs30(5), 1984–1990 (2011).
   PubMed Web of Science ®Google Scholar
• Quinn DI , RuelN, TwardowskiPet al. Eribulin in advanced urothelial cancer (AUC) patients (pts): a California Cancer Consortium trial – NCI/CTEP 7435. J. Clin. Oncol. (Meeting Abstracts)33(15 Suppl.), 4504 (2015).
   Web of Science ®Google Scholar
• Galsky MD , MironovS, IasonosA, ScattergoodJ, BoyleMG, BajorinDF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest. New Drugs25(3), 265–270 (2007).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ , RothBJ, KabbinavarFFet al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol.24(21), 3451–3457 (2006).
   PubMed Web of Science ®Google Scholar
• Massard C , GordonMS, SharmaSet al. Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer, June 2016. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 3–7 June 2016.
   Google Scholar
• Apolo AB , InfanteJR, HamidOet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor Phase Ib trial: analysis of safety, clinical activity, and PD-L1 expression. ASCO Annual Meeting. Chicago, IL, USA, 4–7 June 2016.
   Google Scholar
• Sharma P , BonoP, KimJWet al. Efficacy and safety of nivolumab monotherapy in metastatic mUC: results from the Phase I/II CheckMate 032 study. ASCO Annual Meeting. Chicago, IL, USA, 4–7 June 2016.
   Google Scholar
• Pfirschke C , EngblomC, RickeltSet al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity44(2), 343–354 (2016).
   PubMed Web of Science ®Google Scholar
• Zamarin D , PostowMA. Immune checkpoint modulation: rational design of combination strategies. Pharmacol. Ther.150, 23–32 (2015).
   PubMed Web of Science ®Google Scholar
• Galsky MD . Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. Presented at: 2016 Genitourinary Cancer Symposium. San Fancisco, CA, USA, 7–9 January 2016.
   Google Scholar
• Clinical Trials Database: NCT02437370. https://clinicaltrials.gov/ct2/show/NCT02437370.
   Google Scholar
• Clinical Trials Database: NCT02581982. https://clinicaltrials.gov/ct2/show/NCT02581982.
   Google Scholar
• Abbosh PH , McconkeyDJ, PlimackER. Targeting signaling transduction pathways in bladder cancer. Curr. Oncol. Rep.17(12), 1–10 (2015).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02546661. https://clinicaltrials.gov/ct2/show/NCT02546661.
   Google Scholar
• Clinical Trials Database: NCT02443324. https://clinicaltrials.gov/ct2/show/NCT02443324.
   Google Scholar
• Larkin J , Chiarion-SileniV, GonzalezRet al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med.373(1), 23–34 (2015).
   PubMed Web of Science ®Google Scholar
• Hammers HJ , PlimackER, InfanteJRet al. Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Presented at: ASCO Annual Meeting Proceedings. Chicago, IL, USA, 2–5 June 2015.
   Google Scholar
• Clinical Trials Database: NCT02553642. https://clinicaltrials.gov/ct2/show/NCT02553642.
   Google Scholar
• Clinical Trials Update: NCT01928394. https://clinicaltrials.gov/ct2/show/NCT01928394.
   Google Scholar
• Clinical Trials Database: NCT02516241. https://clinicaltrials.gov/ct2/show/NCT02516241.
   Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02614456. https://clinicaltrials.gov/ct2/show/NCT02614456.
   Google Scholar
• Huang Y , ZhangS-D, MccruddenC, ChanK-W, LinY, KwokH-F. The prognostic significance of PD-L1 in bladder cancer. Oncol. Rep.33(6), 3075–3084 (2015).
   PubMed Web of Science ®Google Scholar
• Powles T , NicklesD, Van AllenEet al. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). J. Immunother. Cancer3(Suppl. 2), P83 (2015).
   Google Scholar